Protagonist Therapeutics (PTGX) is gearing up to report top-line results from its phase 3 VERIFY study using its subcutaneous injectable Hepcidin Mimetic rusfertide [PTG-300] for the treatment of ...

Protagonist Therapeutics remains a high-conviction buy, driven by late-stage assets icotrokinra and rusfertide approaching regulatory milestones in 2026. PTGX’s robust cash position of $678.8 million ...

London-based sales, finance and production company Protagonist Pictures has launched a boutique label on the eve of Cannes. Announced by Protagonist CEO Dave Bishop, Protagonist Picks will be led by ...

From left James Pugh, David Bishop, George Hamilton Protagonist Pictures Welcome to Deadline’s International Disruptors, a feature where we shine a spotlight on key executives and companies outside of ...

Protagonist Pictures has promoted senior execs Janina Vilsmaier and Mounia Wissinger to senior leadership roles as part of a wider move to strengthen its sales and marketing teams. Vilsmaier has been ...